Predictors of Nonuse of a High‐Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib‐Thrombolysis in Myocardial Infarction 52 (SOLID‐TIMI 52) Trial
暂无分享,去创建一个
Dylan L. Steen | E. Braunwald | C. Cannon | M. O’Donoghue | A. Eisen | J. Špinar | M. Lukas | K. Im | Erica L. Goodrich | A. Dalby | Jing Zhou | S. Daga
[1] Jeroen J. Bax,et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.
[2] T. Brown,et al. Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. , 2015, Journal of the American College of Cardiology.
[3] A. Jaffe,et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[4] Solid-Timi Investigators. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. , 2014 .
[5] Jennifer G. Robinson,et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Journal of the American College of Cardiology.
[6] Jennifer G. Robinson,et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[7] J. Spertus,et al. Patterns of Statin Initiation, Intensification, and Maximization Among Patients Hospitalized With an Acute Myocardial Infarction , 2014, Circulation.
[8] Dylan L. Steen,et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. , 2014, JAMA.
[9] V. Fuster,et al. Risk factor control for coronary artery disease secondary prevention in large randomized trials. , 2013, Journal of the American College of Cardiology.
[10] P. Libby,et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial , 2012, The Lancet.
[11] Jeroen J. Bax,et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2012 .
[12] E. Braunwald,et al. Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. , 2011, American heart journal.
[13] T. Lauer,et al. Kardiologische Aspekte der präoperativen Risikostratifizierung , 2011 .
[14] J. Spertus,et al. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. , 2011, JAMA.
[15] Ian Graham,et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, Atherosclerosis.
[16] Deepak L. Bhatt,et al. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospita participating in Get With The Guidelines (GWTG). , 2011, American heart journal.
[17] Deepak L. Bhatt,et al. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). , 2010, American heart journal.
[18] M. Gnant,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .
[19] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[20] C. Cannon,et al. Factors associated with discharge lipid-lowering drug prescription in patients hospitalized for coronary artery disease (from the Get With the Guidelines database). , 2008, The American journal of cardiology.
[21] Christopher E. Buller,et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2008, Circulation.
[22] William Wijns,et al. [Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]. , 2007, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.
[23] J. Ornato,et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patie , 2007, Journal of the American College of Cardiology.
[24] G. Lamas,et al. Focused Update of the ACC / AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction , 2007 .
[25] Philip J. Barter,et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.
[26] M. Pfeffer,et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.
[27] Christopher P Cannon,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[28] Thomas Weber,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.